MDMA therapy was rejected by FDA advisors due to concerns over research

US’ Food and Drug Administration (FDA) said it has rejected an application for MDMA therapy to treat post-traumatic stress disorder (PTSD) amid concerns over research. The drug is currently being tested in Phase II trials, but the advisory panel found no abuse-related injuries or deaths among the patients receiving MDMA. It also raised concerns over the clinical research used for the trials.